P278 Partnering for impact: the cystic fibrosis antimicrobial resistance syndicate

Antimicrobial resistance (AMR) is a leading cause of death globally [1]. Antibiotics remain key and necessary intervention for people with cystic fibrosis (pwCF) particularly as recurrent increasingly multidrug-resistant respiratory infections dominate morbidity mortality [2]. Therefore, there an urgent unmet need the development new antimicrobials to manage in CF. To this end, CF Trust (CFT) partnered Medicines Discovery Catapult (MDC) create Resistance (CF AMR) Syndicate accelerate diagnostics, bringing effective treatment options clinic faster. Recently, LifeArc joined managing partner further strengthen antimicrobial discovery efforts. The alongside pwCF, academics, industry clinical collaborators worked together map innovation landscape tackle hurdles drug developers. An initial scoping exercise across revealed two common hurdles: difficulties accessing appropriate samples data, lack well-defined preclinical pathway. has created toolkit resources address these hurdles, which include strain guidance document; virtual biorepository; therapeutic target product profile (TPP) report, infection diagnostic TPP under development. CFT CFF have also co-funded strategic research center develop evidence-based framework therapeutics (PIPE-CF). launched AMR network critical mass experts exchange knowledge, enable collaborative programs, facilitate involvement pwCF. rapidly gaining momentum its pursuit bring diagnostics